# HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

> **NCT05190068** · PHASE1 · COMPLETED · sponsor: **Hutchmed** · enrollment: 89 (actual)

## Conditions studied

- B-Cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** HMPL-760

## Key facts

- **NCT ID:** NCT05190068
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-04
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-01-27
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190068, "HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05190068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*